<DOC>
	<DOCNO>NCT02831361</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety gemigliptin 50 mg orally administer daily 24 week compare placebo patient type 2 diabetes mellitus inadequate glycemic control insulin alone insulin combination metformin stably 8 week .</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety Gemigliptin Compared With Placebo Added Insulin Alone Insulin Combination With Metformin Type 2 DM ( ZEUS II Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus ≥19 year age time Visit 1 ( Screening ) 2 . Patients HbA1c FPG value measure central laboratory satisfy follow condition time Visit 1 ( Screening ) Patients take OADs metformin within 8 week prior Visit 1 ( Screening ) : 7.0 % ≤ HbA1c ≤ 11 % , FPG &lt; 270mg/dl Patients take OADs metformin within 8 week prior Visit 1 ( Screening ) : 6.5 % ≤ HbA1c ≤ 10.5 % , FPG &lt; 270mg/dl However , retest carry visit window , central laboratory value n't meet criterion mention . 3 . Patients stably receive minimum ≥15 U/day maximum ≤1 U/kg/day insulin ( longacting , intermediateacting premixed ) 8 week prior Visit 1 ( Screening ) ( 'Stably ' defined case mean total daily dose insulin adjust range ±10 % dose use day Visit 1 ( Screening ) 8 week prior Visit 1 ( Screening ) . 4 . For patient take metformin , patient take least 1000 mg metformin daily without dose adjustment 8 week prior Visit 1 ( Screening ) 5 . Patients applicable one three follow . 1 . Surgically infertile patient 2 . Postmenopausal female patient ≥45 year age ≥2 year elapse since last menstruation 3 . Premenopausal fertile female patient surgically noninfertile male patient agree use least 2 kind contraceptive measure ( certainly include one barrier method ) avoid pregnancy 14 day last dose investigational product Barrier method : Condom , Diaphragm , Cervical cap ( Pessary ) , Spermicide Hormonal method : Pills , Injection ( Depot ) , Skin patch , Hormonal implant ( Implanon ) , Vaginal ring Intrauterine Devices ( IUDs ) : Cooper IUD ( Loop ) , Hormonal IUD ( Mirena ) Natural method : Basic body temperature , Ovulation period , Coitus interruptus , Abstinence 6 . Patients sign informed consent receive explanation objective , method , effect , etc . clinical study For patient go washout period , inclusion criterion check Visit 11 ( Screening ) . 7 . Patients whose HbA1c FPG measure Visit 11 ( Screening ) 7.0 % ~11 % &lt; 270 mg/dl , respectively 8 . Patients whose mean daily dose insulin check Visit 11 ( Screening ) range ±10 % dose check Visit 1 ( Screening ) 1 . Patients type 1 diabetes mellitus* , gestational diabetes , secondary diabetes 2 . Patients Body Mass Index ( BMI ) ＞40 kg/m2 time Visit 1 ( Screening ) 3 . Patients history follow Patients experience severe hypoglycaemia within 24 week prior Visit 1 ( Screening ) experience hypoglycaemia least 3 time week within 8 week prior Visit 1 ( Screening ) † Patients history diabetic ketoacidosis hyperosmolar nonketotic coma within 24 week prior Visit 1 ( Screening ) # Patients history myocardial infarction , unstable angina , coronary artery bypass graft ( CABG ) within 24 week prior Visit 1 ( Screening ) Patients NYHA Class III , IV congestive heart failure arrhythmia require treatment time Visit 1 ( Screening ) Patients whose TSH level normal range thyroidal dysfunction require drug therapy time Visit 1 ( Screening ) ( However , take thyroid hormone fix dose since previous 4 week prior Visit 1 [ Screening ] whose TSH level within normal range participate study . ) Patients severe infection severe trauma time Visit 1 ( Screening ) Patients surgical operation within 4 week prior Visit 1 ( Screening ) ( exclude minor surgery without restriction food fluid intake ) schedule significant surgery study period Patients pituitary insufficiency adrenal insufficiency time Visit 1 ( Screening ) Patients pulmonary embolism , severe pulmonary dysfunction , susceptible accompany hypoxemia time Visit 1 ( Screening ) Patients drug therapy due gastrointestinal disturbance include dehydration , diarrhea , vomit time Visit 1 ( Screening ) # Patients positive carrier hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) time Visit 1 ( Screening ) visit Patients history alcoholism drug addiction within 1 year prior Visit 1 ( Screening ) Patients history malignant tumor within 5 year prior Visit 1 ( Screening ) . However , patient basal cell squamous cell skin cancer , situ cervical cancer treat properly participate study . Patients endstage renal disease ( ESRD ) time Visit 1 ( Screening ) 4 . Patients outcomes laboratory test perform Visit 1 ( Screening ) applicable criterion Bilirubin &gt; 1.5 × upper limit normal ( ULN ) AST/ALT &gt; 2.5 × ULN 5 . Male female patient metformin serum creatinine level ≥1.5 mg/dl ≥1.4 mg/dl , respectively time Visit 1 ( Screening ) 6 . Patients history hypersensitivity reaction drug Gemigliptin drug belong dipeptidylpeptidase4 ( DPP4 ) inhibitor Metformin drug belong biguanides Insulin 7 . Patients administer drug Patients administer antiobesity drug within 12 week prior Visit 1 ( Screening ) Patients administer shortacting rapidacting insulin meal within 8 week prior Visit 1 ( Screening ) Patients administer GLP1 analogue within 8 week prior Visit 1 ( Screening ) Patients administer warfarin , dicoumarin , digoxin within 4 week prior Visit 1 ( Screening ) Patients administered glucocorticoid continuously within 2 week prior Visit 1 ( Screening ) require take glucocorticoid continuously future Patients administer strong CYP3A4 inducer ( rifampicin [ rifampin ] , dexamethasone , phenytoin , carbamazepine , rifabutin , phenobarbital ) time Visit 1 ( Screening ) * Patients administer cimetidine time Visit 1 ( Screening ) 8 . Female patient pregnant lactate 9 . Patients experience participation another clinical study within 12 week prior Visit1 ( screen ) 10 . Patients otherwise consider ineligible study investigator ' judgment For patient go washout period , exclusion criterion check Visit 11 ( Screening ) . 11 . Patients whose mean daily dose insulin 8week washout period beyond ±10 % dose check Visit 1 ( Screening ) ≥ 12 day 5 consecutive day At Visit 1 ( Screening ) Visit 11 ( Screening ) , subject meet inclusion/exclusion criterion enter 2week runin period along exercise/diet .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>